, Volume 53, Issue 9, pp 2029–2035 | Cite as

Capillary pressure may predict preclinical changes in the eye

  • K. M. GoodingEmail author
  • J. E. Tooke
  • H. von Lany
  • M. Mitra
  • R. Ling
  • C. I. Ball
  • D. Mawson
  • K. Skinner
  • A. C. Shore
Open Access



Microvascular dysfunction is associated with end-organ damage. Macular oedema is an important component of diabetic retinopathy. Macular thickness can be accurately quantified by optical coherence tomography (OCT), enabling accurate assessment of the macular prior to clinically apparent abnormalities. We investigated whether macular (fovea) thickness in non-diabetic individuals is related to the microvascular variables controlling fluid filtration across a blood vessel wall, in particular capillary pressure and the microvascular filtration capacity (Kf).


We recruited 50 non-diabetic individuals (25 men, 25 women; age range: 26–78 years; BMI range: 20–46 kg/m2). Fovea thickness was assessed by OCT. Microvascular assessments included: finger nailfold capillary pressure; Kf; microvascular structural assessments, i.e. skin vasodilatory capacity, minimum vascular resistance (MVR) and microvascular distensibility; and endothelial function.


At 214.6 (19.9) µm (mean [SD]), fovea thickness was within normal range. Capillary pressure, adjusted for BMI, was associated with fovea thickness (standardised beta 0.573, p = 0.006, linear regression). Fovea thickness was not associated with Kf, microvascular structural assessments or endothelial function. Capillary pressure was still associated with fovea thickness when adjusted for microvascular variables (Kf, vasodilatory capacity, MVR, microvascular distensibility or endothelial function), or for risk factors for diabetes (systemic blood pressure, insulin sensitivity, inflammation, glycaemic status and lipids) and age.


Capillary pressure, a key determinant of movement of fluid across a blood vessel wall, is associated with fovea thickness in non-diabetic individuals. This suggests that with regard to potential preventative or therapeutic targets, attention should be directed at the mechanisms determining retinal microvascular pressure.


Capillary pressure Fluid filtration Fovea thickness Macular oedema Obesity 



Clinically significant macular oedema


Insulin tolerance test


Microvascular filtration capacity


Laser Doppler perfusion imager


Minimum vascular resistance


Optical coherence tomography


The microcirculation is the site where nutrients and waste products are exchanged between the circulation and tissues. Normal microcirculation is vital for tissue health, while abnormalities are associated with disease. In the Atherosclerosis Risk in Communities and other epidemiological studies, clinically apparent retinal structural microvascular abnormalities (including non-diabetic retinopathy) were, for example, independently related to risk of diabetes [1, 2, 3, 4, 5], impaired fasting hyperglycaemia [1, 6], stroke [7, 8, 9, 10, 11], magnetic resonance imaging-defined subclinical cerebral infarcts [12], progression of cerebral small vessel disease [1], congestive heart failure [4], coronary heart disease and acute myocardial infarction [5, 8, 11], left ventricular hypertrophy [13] and cardiovascular mortality rates [14].

However, it is not only these clinically apparent structural abnormalities in the retinal microcirculation that are related to clinical outcomes and/or risk. In the periphery, functional impairments in the small vessels, such as impaired endothelial function of the forearm resistance blood vessels or impaired skin microcirculatory responsiveness, are associated with cardiovascular risk factors [15, 16] and end-organ damage (intraventricular septal thickness or urinary albumin excretion) [17].

Indeed, graded abnormalities in the reactive hyperaemic response of the skin occur across levels of urinary albumin excretion rate from 2 to 20 µg/min, i.e. within the normal range [18]. These associations indicate that subtle abnormalities of microvascular function may run parallel to early evidence of end-organ damage even prior to presentation of clinical disorders.

Diabetic retinopathy remains a leading cause of blindness with maculopathy being the most resistant to amelioration. Macular (fovea) thickening is a preclinical sign of macular oedema, which can be quantified using the new, revolutionary technique of retinal optical coherence tomography (OCT).

This study investigated the mechanisms underlying preclinical changes in fovea thickness, and in particular the roles of the variables that can control fluid movement across the blood vessel wall, e.g. capillary pressure and microvascular filtration capacity (Kf).



We recruited 50 non-diabetic individuals (age range 26 to 78 years) from the local community by advertisements for this study (participant characteristics, see Table 1). Exclusion criteria were diabetes, overt cardiovascular disease, Raynaud’s phenomenon, age less than 18 or over 80 years, and use of any anti-hypertensive, oral hypoglycaemic or lipid-lowering therapies. Seven of the participants had the metabolic syndrome, as defined by the International Diabetes Federation [19]. None of the participants had clinically defined microalbuminuria. Only one participant smoked (cigars), but this participant refrained from smoking on the mornings of the study. Ethics approval was granted by the Local Exeter and North Devon Medical Research Ethics Committee, and written informed consent was obtained from all participants. The studies conformed to the principles outlined in the Declaration of Helsinki.
Table 1

Participant characteristics


Mean (SD)


Total sample (n)

50 (25)


Men (n)



Age (years)

53.5 (11.8)

26 to 78

BMI (kg/m2)

28.6 (6.1)

20 to 46

Waist circumference (cm)

94.4 (15.8)

69 to 139

Systolic blood pressure (mmHg)

124 (16)

87 to 162

Diastolic blood pressure (mmHg)

75.2 (9.4)

59 to 95

Fasting glucose (mmol/l)

4.9 (0.5)

4.0 to 6.9

HbA1c (%)

5.5 (0.4)

3.9 to 6.3

Total cholesterol (mmol/l)

5.37 (0.84)

3.7 to 7.4

HDL-cholesterol (mmol/l)

1.54 (0.42)

0.72 to 2.32

LDL-cholesterol (mmol/l)

3.21 (0.62)

2.17 to 5.22

Triacylglycerol (mmol/l)

1.19 (0.46)

0.46 to 2.40

ACR (mg/mmol)

0.62 (0.27)

0.22 to 1.44


5.35 (2.82)

2.11 to 15.36

Inflammation markers


 C-reactive protein (ng/ml)

982 (1,293)

24 to 5,578

Measures of insulin sensitivity


 ITT (mmol l−1 min−1)

−0.22 (0.08)

−0.53 to −0.11

 Insulin sensitivity (HOMA) (%)

130 (74)

16 to 318

ACR, albumin:creatinine ratio


Participants attended the study visits in the morning following an overnight fast. The following assessments were spread over two to three mornings: macular thickness, retinal photography, capillary pressure, Kf, microvascular structural assessments (vasodilatory capacity, minimum vascular resistance [MVR], microvascular distensibility), resting skin perfusion, microvascular endothelial function and supine blood pressure (mean of three measurements taken at 1 min intervals). The vascular assessments were performed in temperature-controlled microvascular laboratories with the participants in a supine position following a 30 min acclimatisation period.

Macular thickness

OCT was used to quantify retinal thickness (Stratus OCT 3000; Carl Zeiss, Welwyn Garden City, UK) using the fast macular thickness scanning protocol following pupil dilation in both eyes. OCT measures the macular thickness between the vitreoretinal interface and the interface between the inner and outer photoreceptors segments by changes in reflectivity from the reflected light (original light source: broad bandwidth near infrared light beam with central wavelength of 820 nm). The Stratus OCT software (version 4.0.7) automatically determines the thickness of the subdivisions of the macula (fovea; inner and outer quadrants of the superior, nasal, inferior and temporal regions) and the volume of the total macular area. The fovea was defined as the central disc of the scan, with a radius of 500 µm. This technique is reproducible in healthy participants [20]. In our hands, the intra-individual coefficient of variation for the assessment of fovea thickness was 2.6% (182.0 [4.8] µm, mean [SD]) determined from one participant on four separate occasions.

Capillary pressure

Finger nailfold capillary pressure was measured following direct cannulation of the apex of the capillary loop with a glass micropipette. Dynamic recordings of capillary pressure were achieved using an electronic resistance feedback servo-nulling system [21]. Day-to-day intra-participant variation of the measurement of capillary pressure was 5.2% (3.6%) in six individuals studied on three separate occasions.

Microvascular filtration capacity

Kf was determined using strain-gauge plethysmography (Filtrass 2001; Domed Medizintechnik, Munich, Germany) [22]. The system uses an occlusion cuff placed proximal (thigh) to the filtrass sensor to monitor changes in calf circumference and hence volume in response to increases in venous congestion pressure. The calf circumference is continuously monitored throughout a series of small pressure increases of 8 mmHg that in total do not exceed diastolic pressure. As the venous congestion pressure increases, the net movement of fluid across the vessel wall into the interstitium, that is fluid filtration, increases. The relationship between fluid filtration and cuff pressure is linear, with the slope representing Kf. The mean day-to-day intra-participant variation in the measurement of Kf using this system was 7.1% in two healthy participants assessed on four separate occasions (2.37 ± 0.21 × 10−3 and 2.90 ± 0.15 × 10−3 ml min−1 [100 ml]−1 mmHg−1, mean ± SD, for participants 1 and 2 respectively).

Structural microvascular assessments: vasodilatory capacity, minimum vascular resistance and microvascular distensibility

Maximum hyperaemia was assessed by heating a small area of skin to 42 to 44°C [23], which induces maximum hyperaemia and reflects the vasodilatory capacity of the skin microcirculation. This was achieved by attaching a small brass heater (area 0.76 cm2) (Moor Instruments, Axminster, UK) to the dorsum of the foot for 30 min. The resultant maximum hyperaemic response was assessed by single point laser Doppler fluximetry (Perflux Pf2: Perimed, Jarfalla, Sweden), with eight equally spaced measurements being made within the heated area and the mean used to represent vasodilatory capacity, arbitrarily expressed as volts. The foot was then lowered by 50 cm and blood flow reassessed in the eight sites in the dependent position. Microvascular distensibility was calculated by dividing dependent vasodilatory capacity by horizontal vasodilatory capacity. The mean day to day intra-participant coefficient of variation for vasodilatory capacity in three participants assessed on five separate occasions was 6.6%; in a male participant assessed over a 2 year period using laser Doppler fluximetry, it was 7.1% (2.11 [0.15] arbitrary units, mean [SD]). MVR was calculated by dividing the mean arterial blood pressure by vasodilatory capacity.

Endothelial function

Endothelial function was assessed by iontophoretic application of the endothelial-dependent vasodilator acetylcholine [24]. Iontophoresis delivers the drug of interest to the skin using a small electric charge. Briefly, a perspex chamber, with an internal area of 0.76 cm2 available for iontophoresis, was attached to the volar aspect of the forearm and an indifferent electrode (hydro gel pad) attached to the wrist. An electric charge was applied using a battery powered iontophoresis controller (MIC-1; Moor instruments, Axminster, UK) to transfer the study drug across the skin. To assess the microvascular effect of acetylcholine, 1% acetylcholine (Miochol-E; Novartis Pharmaceuticals, Horsham, UK) was iontophoresed at one site and its vehicle, mannitol (3%) (Royal Devon and Exeter Hospital Pharmacy, Exeter, UK), was iontophoresed at another site. The protocol involved the application of a positive charge for five 20 s pulses of 100 µA, with a 60 s rest period between each pulse, making a total charge of 10 mC. The skin hyperaemic response was quantified by a laser Doppler perfusion imager (LDPI) (LDPI Pim 2.0; Perimed, Jarfalla, Sweden). Skin hyperaemia was assessed at baseline and then every 40 s for 400 s after the start of the charge. The LDPI perfusion images were saved for later off-line analysis. For each image, the mean perfusion over the entire iontophoresed area (0.76 cm2) was calculated with LDPI Win 2.0.9 software (Perimed) and arbitrarily expressed as volts. The results are expressed as the peak hyperaemic response. Resting skin perfusion was determined from baseline scan taken at the mannitol (acetylcholine vehicle) site.

Insulin sensitivity assessments

Central insulin sensitivity was calculated by HOMA of insulin sensitivity, based on fasting insulin and glucose levels [25]. Peripheral insulin sensitivity was assessed using a 15 min continuous insulin tolerance test (ITT). A bolus of 0.1 U/kg insulin (Human Actrapid; Novo Nordisk, Crawley, UK) was administered into a vein at the site of the antecubital fossa. Blood samples for determination of blood glucose were taken each minute until the blood glucose level reached 3 mmol/l or 15 min duration was reached. The glucose samples were measured in duplicate (YSI2300 Stat Plus; YSI Life Sciences, Yellowsprings, OH, USA). The slope of the blood glucose curve was used to represent insulin sensitivity. Mean day-to-day intra-participant variation of the measurement of insulin sensitivity by ITT was 18% in four individuals studied on three separate occasions.

Haemostatic and urine assessments

Standard haemostatic and urine measurements included: HbA1c (normal range 4.0–6.0%); fasting glucose; lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol and triacylglycerol); urinary creatinine; and urinary albumin. A urine albumin excretion rate of 20 to 200 µg/min or an albumin:creatinine ratio ≥2.5 mg/mmol (men) or ≥3.5 mg/mmol (women) was regarded as clinical cut-off for microalbuminuria. Additional assessments included fasting plasma insulin (0.05% cross-reactivity with human proinsulin) (Cobas; Roche, Burgess Hill, UK) and C-reactive protein (Vascular injury panel II plate; Meso Scale Discovery, Gaithersburg, MD, USA).

Statistical analysis

Data are presented as mean (SD) unless stated otherwise. Fovea thickness was our primary outcome measure, as it is the only region of the macular that is independently associated with macular oedema [26]. As there was no difference in fovea thickness or intraocular pressure between right and left eye, data from both eyes were averaged and used in subsequent data analysis. Univariate analysis (Pearson’s or Spearman’s correlation test, dependent on normality of data) was used to explore whether fovea thickness was associated with the following microvascular variables: capillary pressure, Kf, vasodilatory capacity, MVR, microvascular distensibility, resting skin perfusion and endothelial function. Significant associations from univariate analysis were then further explored using linear regression, adjusting for BMI as it is well known that obesity influences measures of microvascular variables [27, 28] (K. M. Gooding, J. E. Tooke and A. C. Shore, unpublished observations). With a sample size of 50, the study was powered to detect, with up to three predictors in a model, a large effect size (f 2 = 0.33) at the 5% level with 90% power.


Fovea thickness was within the normal range defined by Chan et al [29] using the OCT 3000 system in all participants. There was no evidence of diabetes-related retinal abnormalities or ocular neurodegenerative disorders in any of the participants. Results are presented in Table 2.
Table 2

Results from eye and vascular assessments for the entire group


Mean (SD)


Fovea thickness (µm)

214.6 (19.9)


Intraocular pressure (mmHg)

15.1 (3.2)


Capillary pressure (mmHg)

16.6 (3.8)


Kf (10−3 ml min−1 [100 ml]−1 mmHg−1)

3.58 (0.97)


MVR (mmHg/V)

52.6 (21.3)


Vasodilatory capacity (V)

1.93 (0.64)


Microvascular distensibility

1.23 (0.21)


Resting skin perfusion (V)

0.18 (0.07)


Peak endothelial-dependent skin perfusion (V)

1.06 (0.27)


Relationships between fovea thickness and microvascular variables

Capillary pressure was significantly associated with fovea thickness (r = 0.379, p = 0.027, Model 1) (Table 3). This relationship was strengthened when the model was adjusted for BMI (Model 2) (Fig. 1). The relationship between capillary pressure and fovea thickness adjusted for BMI was not explained by (1) Kf (Model 3); (2) structural effects (vasodilatory capacity, MVR, microvascular distensibility) (capillary pressure standardised beta ≥0.547, p ≤ 0.009, Models 6–8) (Electronic supplementary material [ESM] Table 1); (3) resting skin perfusion (capillary pressure standardised beta 0.599, p = 0.006, Model 9) (ESM Table 1); or (4) endothelial function (standardised beta 0.562, p = 0.008, Model 10) (ESM Table 1). Neither Kf nor any of the other microvascular variables were independently associated with fovea thickness. In addition, no significant associations were observed between any of the microvascular variables and the inner and outer quadrants of the macular.
Table 3

Associations between fovea thickness and variables as indicated

Associations per model

R 2

p value for overall model

Unstandardised beta (SE)

Standardised beta

p values for individual predictors

Model 1




 Capillary pressure


2.067 (0.892)



Model 2




 Capillary pressure


3.166 (1.07)





−1.02 (0.585)



Model 3




 Capillary pressure


2.897 (1.222)





−1.119 (4.799)





−1.042 (0.652)



Model 4




 Capillary pressure


3.470 (1.050)





−1.239 (0.598)



 Mean arterial blood pressure


0.405 (0.344)



Model 5




 Capillary pressure


2.758 (1.11)





−0.999 (0.555)



 Intraocular pressure


1.867 (1.012)



Fig. 1

Association between capillary pressure and fovea thickness. Each marker represents an individual participant. Continuous line, regression line between capillary pressure and fovea thickness (r = 0.379, p = 0.027); dashed line, regression line between capillary pressure and fovea thickness when adjusted for BMI (r = 0.463, p = 0.021)

Explaining the relationship between fovea thickness and capillary pressure

The relationship between capillary pressure adjusted for BMI and fovea thickness was not explained by mean arterial pressure (Model 4), systolic or diastolic blood pressure (results not shown) or by intraocular pressure (Model 5). In addition, the relationship between capillary pressure adjusted for BMI and fovea thickness was not explained by age (capillary pressure standardised beta 0.568, p = 0.008), inflammation (C-reactive protein; capillary pressure standardised beta 0.544, p = 0.011), insulin sensitivity (ITT, capillary pressure standardised beta −0.483, p ≤ 0.022; HOMA, capillary pressure standardised beta −0.489, p ≤ 0.038), glycaemic status (HbA1c and fasting glucose) (capillary pressure standardised beta ≥0.545, p ≤ 0.030) or lipids (capillary pressure standardised beta ≥0.513, p ≤ 0.019).


This study has demonstrated for the first time that capillary pressure, the key determinant of movement of fluid across a blood vessel wall, is positively associated with fovea thickness in non-diabetic individuals. None of the other microvascular determinants of fluid filtration such as Kf were associated with fovea thickness. In addition, the inner and outer quadrants of the macular were not significantly associated with any of the microvascular variables.

Alterations in fovea thickness (an early sign of macular oedema) are likely to result from changes in transmural capillary fluid movement, which is governed by the balance of hydrostatic and oncotic forces acting across the capillary wall, as described in Starling’s equation [30]. Capillary pressure remained associated with fovea thickness when adjusted for intraocular pressure as well as for BMI. Interestingly, the addition of intraocular pressure to the model increased the amount of variance explained by the model from 22% to 34%. Our observation that a raised hydrostatic capillary pressure capable of promoting fluid filtration is associated with an increase in fovea thickness suggests that alterations in capillary pressure may play an instrumental role in the development of macular oedema. This would be in keeping with the importance previously ascribed to capillary pressure in the movement of fluid across the healthy vessel wall, as capillary pressure is known to be the most variable of Starling’s forces. These observations suggest that when it comes to potential preventative or therapeutic targets, attention should be directed at the mechanisms determining retinal microvascular pressure.

Microvascular filtration capacity, a component of Starling’s equation governing fluid filtration, was not associated with fovea thickness and also did not contribute to the relationship between capillary pressure and fovea thickness. Fovea thickness is thus independent of changes in the surface area available for exchange and permeability of the vessel wall (hydraulic conductance), which determine Kf in non-diabetic, healthy individuals. This observation that structural changes in the microvasculature are not associated with fovea thickness, either independently or in conjunction with capillary pressure, is supported by the lack of relationship of vasodilatory capacity, MVR and microvascular distensibility with fovea thickness in this study. Resting skin perfusion and endothelial function were not associated with fovea thickness. In addition, they did not account for the effect of capillary pressure on fovea thickness, suggesting that this relationship is independent of microvascular skin perfusion.

Acute alterations in fovea thickness have been reported in connection with posture in type 2 diabetes patients with clinically significant macular oedema (CSMO), with the fovea being thicker in the morning and decreasing in thickness during the day and evening [31, 32]. Posture-induced changes in hydrostatic pressure have been proposed to account for these alterations. This is supported by the observation that fovea thickness decreased by a greater magnitude in individuals in the sitting position than in those in the supine position over the course of the day [33]. Changes in venous and capillary pressure are believed to be the main contributors to posture-induced alterations in fovea thickness in type 2 diabetic patients with CSMO [32, 33]. The data in the present study support the importance of capillary pressure in regulation of fovea thickness as was hypothesised in these studies of postural aspects.

Systemic blood pressure did not contribute to the relationship between capillary pressure and fovea thickness, as the relationship remained when controlling for mean, systolic and diastolic arterial blood pressure. This finding is not unexpected as in healthy individuals capillary pressure is independent of arterial blood pressure due to the autoregulation that protects the microcirculation from acute upstream changes in pressure [34]. In contrast, the posture-induced changes to fovea thickness in type 2 diabetic individuals with CSMO have been shown to be independent and dependent of systemic arterial blood pressure [32, 33]. A possible explanation for the potential contribution of arterial blood pressure to posture-induced changes in fovea thickness is a failure of autoregulation in type 2 diabetic patients with retinopathy and macular oedema [35].

Body composition, as reflected by BMI, influenced the relationship between capillary pressure and fovea thickness, as capillary pressure explained more of the variance in fovea thickness when controlling for BMI. This suggests that BMI may mask the effects of capillary pressure on fovea thickness. In fact, there was a consistent trend for increased BMI to be associated with a reduction in fovea thickness. A potential explanation of the negative relationship between BMI and fovea thickness is neurodegeneration, which is associated with obesity [36]. Fovea thickness is reduced in individuals with multiple sclerosis [37]. It is also negatively related to duration of diabetes in type 2 diabetic patients with no or mild retinopathy, a finding thought to reflect neurodegeneration in the diabetic retina [38].

A limitation of the current study is the potential for a type 2 error. However, the fact that capillary pressure was consistently associated with fovea thickness in all models endorses the proposal that an increase in capillary pressure is associated with an increase in fovea thickness.

In summary, this study has shown for the first time that capillary pressure, the key determinant of fluid filtration across the blood vessel, is associated with fovea thickness in non-diabetic individuals. This relationship is independent of arterial and intraocular pressure, BMI, microvascular skin perfusion, Kf, structural changes in the microvasculature, inflammation, glycaemic status, insulin sensitivity and lipids. Thus, our findings support the concept that preclinical changes in microvascular function may be linked with end-organ damage, in this case fovea thickness. They also suggest that in terms of potential preventative or therapeutic targets, attention should be directed at the mechanisms determining retinal microvascular pressure.



This study was funded by Diabetes UK and supported by the Peninsula NIHR Clinical Research Facility at the University of Exeter. The opinions given in this paper do not necessarily represent those of the NIHR, the NHS or the Department of Health. We are grateful to R. MacLeod for undertaking the retinal photographs and to D. Bedford for her administrative support.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Supplementary material

125_2010_1805_MOESM1_ESM.pdf (36 kb)
ESM Table 1 (PDF 36 kb)


  1. 1.
    Ikram MK, Janssen JA, Roos AM et al (2006) Retinal vessel diameters and risk of impaired fasting glucose or diabetes: the Rotterdam study. Diabetes 55:506–510CrossRefPubMedGoogle Scholar
  2. 2.
    Klein R, Klein BE, Moss SE, Wong TY (2006) The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. Trans Am Ophthalmol Soc 104:98–107PubMedGoogle Scholar
  3. 3.
    Nguyen TT, Wang JJ, Islam FM et al (2008) Retinal arteriolar narrowing predicts incidence of diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study. Diabetes 57:536–539CrossRefPubMedGoogle Scholar
  4. 4.
    Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD (2005) Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. Arch Intern Med 165:1060–1065CrossRefPubMedGoogle Scholar
  5. 5.
    Wong TY, Klein R, Sharrett AR et al (2002) Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 287:2528–2533CrossRefPubMedGoogle Scholar
  6. 6.
    Kifley A, Wang JJ, Cugati S, Wong TY, Mitchell P (2008) Retinal vascular caliber and the long-term risk of diabetes and impaired fasting glucose: the Blue Mountains Eye Study. Microcirculation 15:373–377CrossRefPubMedGoogle Scholar
  7. 7.
    Mitchell P, Wang JJ, Wong TY, Smith W, Klein R, Leeder SR (2005) Retinal microvascular signs and risk of stroke and stroke mortality. Neurology 65:1005–1009CrossRefPubMedGoogle Scholar
  8. 8.
    Wang JJ, Liew G, Klein R et al (2007) Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations. Eur Heart J 28:1984–1992CrossRefPubMedGoogle Scholar
  9. 9.
    Witt N, Wong TY, Hughes AD et al (2006) Abnormalities of retinal microvascular structure and risk of mortality from ischemic heart disease and stroke. Hypertension 47:975–981CrossRefPubMedGoogle Scholar
  10. 10.
    Wong TY, Klein R, Couper DJ et al (2001) Retinal microvascular abnormalities and incident stroke: the atherosclerosis risk in communities study. Lancet 358:1134–1140CrossRefPubMedGoogle Scholar
  11. 11.
    Wong TY, Klein R, Sharrett AR et al (2003) The prevalence and risk factors of retinal microvascular abnormalities in older persons: The Cardiovascular Health Study. Ophthalmology 110:658–666CrossRefPubMedGoogle Scholar
  12. 12.
    Cooper LS, Wong TY, Klein R et al (2006) Retinal microvascular abnormalities and MRI-defined subclinical cerebral infarction: the Atherosclerosis Risk in Communities Study. Stroke 37:82–86CrossRefPubMedGoogle Scholar
  13. 13.
    Tikellis G, Arnett DK, Skelton TN et al (2008) Retinal arteriolar narrowing and left ventricular hypertrophy in African Americans. The Atherosclerosis Risk in Communities (ARIC) study. Am J Hypertens 21:352–359CrossRefPubMedGoogle Scholar
  14. 14.
    Wong TY, Klein R, Nieto FJ et al (2003) Retinal microvascular abnormalities and 10-year cardiovascular mortality: a population-based case–control study. Ophthalmology 110:933–940CrossRefPubMedGoogle Scholar
  15. 15.
    Chan NN, Colhoun HM, Vallance P (2001) Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol 38:1814–1820CrossRefPubMedGoogle Scholar
  16. 16.
    Ijzerman RG, de Jongh RT, Beijk MAM et al (2003) Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Investig 33:536–542CrossRefGoogle Scholar
  17. 17.
    Strain WD, Chaturvedi N, Leggetter S et al (2005) Ethnic differences in skin microvascular function and their relation to cardiac target-organ damage. J Hypertens 23:133–140CrossRefPubMedGoogle Scholar
  18. 18.
    Strain WD, Chaturvedi N, Bulpitt CJ, Rakijumar C, Shore AC (2005) Albumin excretion rate and cardiovascular risk: could the association be explained by early microvascular dysfunction? Diabetes 54:1816–1822CrossRefPubMedGoogle Scholar
  19. 19.
    Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480CrossRefPubMedGoogle Scholar
  20. 20.
    Paunescu LA, Schuman JS, Price LL et al (2004) Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using StratusOCT. Invest Ophthalmol Vis Sci 45:1716–1724CrossRefPubMedGoogle Scholar
  21. 21.
    Shore AC, Sandeman DD, Tooke JE (1995) Capillary pressure, pulse pressure amplitude, and pressure waveform in healthy volunteers. Am J Physiol 268:H147–H154PubMedGoogle Scholar
  22. 22.
    Gamble J, Gartside IB, Christ F (1993) A reassessment of mercury in silastic strain gauge plethysmography for microvascular permeability assessment in man. J Physiol 464:407–422PubMedGoogle Scholar
  23. 23.
    Gooding KM, Hannemann MM, Tooke JE, Clough GF, Shore AC (2006) Maximum skin hyperaemia induced by local heating: possible mechanisms. J Vasc Res 43:270–277CrossRefPubMedGoogle Scholar
  24. 24.
    Morris SJ, Shore AC, Tooke JE (1995) Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 38:1337–1344CrossRefPubMedGoogle Scholar
  25. 25.
    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMedGoogle Scholar
  26. 26.
    Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montanes J, Garcia-Layana A (2002) Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 43:1588–1594PubMedGoogle Scholar
  27. 27.
    Clough GF, Turzyniecka M, Walter L et al (2009) Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment. Diabetes 58:1185–1191CrossRefPubMedGoogle Scholar
  28. 28.
    Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD (2007) Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda, MD) 22:252–260Google Scholar
  29. 29.
    Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 124:193–198CrossRefPubMedGoogle Scholar
  30. 30.
    Michel CC (1997) Starling: the formulation of his hypothesis of microvascular fluid exchange and its significance after 100 years. Exp Physiol 82:1–30PubMedGoogle Scholar
  31. 31.
    Frank RN, Schulz L, Abe K, Iezzi R (2004) Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 111:211–217CrossRefPubMedGoogle Scholar
  32. 32.
    Larsen M, Wang M, Sander B (2005) Overnight thickness variation in diabetic macular edema. Invest Ophthalmol Vis Sci 46:2313–2316CrossRefPubMedGoogle Scholar
  33. 33.
    Polito A, Del Borrello M, Polini G, Furlan F, Isola M, Bandello F (2006) Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT. Retina 26:14–20CrossRefPubMedGoogle Scholar
  34. 34.
    Shore AC, Sandeman DD, Tooke JE (1993) Effect of an increase in systemic blood pressure on nailfold capillary pressure in humans. Am J Physiol 265:H820–H823PubMedGoogle Scholar
  35. 35.
    Frederiksen CA, Jeppesen P, Knudsen ST, Poulsen PL, Mogensen CE, Bek T (2006) The blood pressure-induced diameter response of retinal arterioles decreases with increasing diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol 244:1255–1261CrossRefPubMedGoogle Scholar
  36. 36.
    Bruce-Keller AJ, Keller JN, Morrison CD (2009) Obesity and vulnerability of the CNS. Biochim Biophys Acta 1792:395–400PubMedGoogle Scholar
  37. 37.
    Gugleta K, Mehling M, Kochkorov A et al (2008) Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis. Klin Monatsbl Augenheilkd 225:408–412CrossRefPubMedGoogle Scholar
  38. 38.
    Asefzadeh B, Fisch BM, Parenteau CE, Cavallerano AA (2008) Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy. Clin Exp Ophthalmol 36:455–463CrossRefGoogle Scholar

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • K. M. Gooding
    • 1
    • 2
    Email author
  • J. E. Tooke
    • 1
  • H. von Lany
    • 3
  • M. Mitra
    • 3
  • R. Ling
    • 3
  • C. I. Ball
    • 1
    • 2
  • D. Mawson
    • 1
    • 2
  • K. Skinner
    • 1
    • 2
  • A. C. Shore
    • 1
    • 2
  1. 1.Diabetes and Vascular Medicine, Institute of Biomedical and Clinical SciencePeninsula Medical SchoolExeterUK
  2. 2.Peninsula National Institute of Health Research Clinical Research FacilityExeterUK
  3. 3.West of England Eye UnitRoyal Devon and Exeter NHS Foundation TrustExeterUK

Personalised recommendations